Monday, November 16, 2026Sign in
The Global Chalet news hub

‹ News

biohacking

Synchron Pauses Stentrode Brain-Computer Interface Trial Enrollment Over Lead Performance Issue

Confirmed·
Photo: insidebci.com

Endovascular brain-computer interface developer Synchron has voluntarily paused enrollment in clinical trials of its second-generation wireless Stentrode implant after identifying a performance problem with the lead connecting the blood-vessel electrode array to the implanted electronics, Inside BCI and The World of Implantable Devices reported on November 13, 2026, citing a November 12 WIRED report.

In a statement, Synchron emphasized that the issue involves the connecting cable rather than the Stentrode stent array itself, that no patient safety problems have been identified, and that the U.S. Food and Drug Administration did not order the pause. The company is bringing lead design and manufacturing in-house and scaling back its New York footprint while recruiting 13 engineering and lead-assembly roles in San Diego to upgrade the full Stentrode system and develop a catheter-delivered multi-region brain interface.

The pause affects Synchron's multisite studies launched in spring 2026 ahead of an FDA pivotal trial: the 10-patient U.S. INTENT study across five hospitals (Mayo Clinic Jacksonville, University at Buffalo, Mount Sinai, UPMC, and UT Southwestern) and the 10-patient Australian FOCUS-AUS trial at Royal Melbourne Hospital, while its two-hospital Toronto study (FOCUS-CAN) was listed as terminated on September 25 after enrolling one participant.

Where this came from
insidebci.com · Read the original ↗
We write a short summary in our own words. The original has the full story.

More about biohacking